Skip NavigationSkip to Content

Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening

  1. Author:
    Ogino, S.
    Wilson, R. B.
    Gold, B.
    Hawley, P.
    Grody, W. W.
  2. Author Address

    Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Univ Penn, Ctr Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. NCI, Human Genet Sect, Lab Genomic Divers, Frederick, MD 21701 USA. Childrens Hosp, Dept Med, Boston, MA 02115 USA. Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Lab Med Human Genet & Pediat, Los Angeles, CA 90024 USA Ogino, S, Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA
    1. Year: 2004
    2. Date: SEP-OCT
  1. Journal: Genetics in Medicine
    1. 6
    2. 5
    3. Pages: 439-449
  2. Type of Article: Article
  1. Abstract:

    Purpose: Risk assessment is an essential component of genetic counseling and testing, and Bayesian analysis plays a central role in complex risk calculations. We previously developed generalizable Bayesian methods to calculate the autosomal recessive disease risk of a fetus when one or no mutation is detected, and another, independent risk factor is present. Our methods are particularly useful for calculating the CF disease risk for a fetus with echogenic bowel. In genetics practice, however, there are other scenarios for which our previous methods are inadequate. Methods and Results: We provide herein methods for calculating genetic risks in a variety of common clinical scenarios. These scenarios include the following: (1) different mutation panels that have been used for the parents and for a fetus; (2) genetic testing results available on the proband or other relatives, in addition to the consultand; (3) fetal ultrasound negative for echogenic bowel with a positive family history; and (4) a consultand with a mixed ethnic background. Conclusion: Our Bayesian methods have proven their versatility through application to many different common genetic counseling scenarios. These methods permit autosomal recessive disease and carrier probabilities to be calculated accurately, taking into account all relevant information. Our methods allow accurate genetic risk estimates for patients and their family members for CF or other autosomal recessive disorders

    See More

External Sources

  1. WOS: 000223965400008

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel